Skip to content
Search

Latest Stories

RPS proposes transition to Royal College, seeks feedback from pharmacy community

RPS proposes transition to Royal College, seeks feedback from pharmacy community

The proposed changes will need approval from RPS members through a vote, which is anticipated in early 2025

The Royal Pharmaceutical Society (RPS), the professional leadership body for pharmacists and pharmaceutical scientists in Great Britain, has today announced its proposal to transition into a royal college, becoming the Royal College of Pharmacy.

This move follows an 18-month independent review of the RPS constitution and governance and is aimed at strengthening the RPS's leadership role to better support its members.


The organisation proposes to enhance its core activities in education, assessment, credentialing, and setting professional standards, ultimately benefiting patients and the public.

Under the proposed new structure, the RPS’s knowledge business, Pharmaceutical Press, would become a wholly owned subsidiary called Pharmaceutical Press Ltd, accountable to the charitable body of the Royal College of Pharmacy.

RPS President Professor Claire Anderson said:  "Pharmacy is changing rapidly and the expectations placed upon pharmacists and the wider pharmacy team will have profound repercussions in terms of delivering patient care.

“It’s time for pharmacy to take its place alongside other health and medical professional leadership bodies and for RPS to become the Royal College of Pharmacy.”

She added that the transformation to a Royal College will reinforce the RPS’s mission and enhance its capacity.

“Becoming a Royal College is a natural progression, reinforcing our commitment to our members and enhancing our capacity to serve patients and the public.

“It will empower us to better advocate for pharmacy and deliver our mission and vision; ensuring that we are always at the forefront of the safe and effective use of medicines.”

RPS plans to hold a series of engagement events across Great Britain starting in October and running over two months to provide details about the proposed changes and gather feedback.

The proposed changes will require approval from RPS members through a vote before they can be submitted to the Privy Council for amendments to the organisation's current Royal Charter and to charity regulators.

The vote is anticipated to take place in early 2025, with a two-thirds majority needed from voting members to move the changes forward.

RPS Chief Executive Paul Bennett emphasised that the proposed change in status reflects the organisation's commitment to upholding the highest standards of professional leadership and patient care.

“It will enable us to be more agile, collaborative and influential across healthcare. As a Royal College, we will have a stronger platform to advance the profession, push for the best possible outcomes for patients and support our members through a rapidly evolving environment,” he said.

The RPS is inviting feedback from the pharmacy community on these proposals and encourages everyone to participate in shaping the organisation’s future.

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less